AOD-9604 vs Alternatives Compared to GHRH analogs such as tesamorelin or CJC-1295, which act upstream by stimulating pituitary GH release and downstream IGF-1, AOD-9604 operates further down the pathway with a narrower receptor footprint
3B), 11 mg/kg (FIG
Unlike pharmacological interventions that target single receptors or pathways, GHK-Cus multi-gene modulation touches many of the hallmarks of aging simultaneously: Genomic instability (DNA repair gene upregulation) Epigenetic alterations (chromatin remodeling via altered transcription factor activity) Loss of proteostasis (chaperone and proteasome pathway modulation) Cellular senescence (anti-apoptotic and anti-senescence gene networks) Altered intercellular communication (anti-inflammatory cytokine modulation) This positions GHK-Cu within what researchers increasingly call multi-hallmark peptide therapy a conceptual framework that prioritizes compounds acting across multiple aging mechanisms simultaneously
In some embodiments, the formulation or composition has a viscosity of at least about 10 cP, about 20 cP, about 30 cP, about 40 cP, about 50 cP, about 60 cP, about 70 cP, about 80 cP, about 90 cP, about 100 cP, about 200 cP, about 300 cP, about 400 cP, about 500 cP, about 600 cP, about 700 cP, about 800 cP, about 900 cP, about 1,000 cP, about 2,000 cP, about 3,000 cP, about 4,000 cP, about 5,000 cP, about 6,000 cP, about 7,000 cP, about 8,000 cP, about 9,000 cP, about 10,000 cP, about 15,000 cP, or about 20,000 cP
